RESUMO
BACKGROUND: There is some interest in long-term survival after various cardiac surgical strategies, including off-pump versus on-pump coronary artery surgery (CAG), mitral valve (MV) repair versus replacement, and aortic valve (AV) bioprosthetic versus mechanical replacement. METHODS: We studied patients older than 49 years of age, recording risk factors and surgical details at the time of surgery. We classified procedures as: MV surgery with or without concurrent grafts or valves; AV surgery with or without concurrent CAG; or isolated CAG. Follow-up was through the state death register and state-wide hospital attendance records. Risk-adjusted survival was estimated using Cox proportional hazards. Observed survival was compared to the expected age- and sex- matched population survival. RESULTS: During a median follow-up of 14.8 years 5,807 of 11,718 patients died. The difference between observed and expected survival varied between 3.4 years for AV surgery and 9.6 years for females undergoing MV surgery. The risk-adjusted mortality hazard rate after off-pump CAG was 0.93 (95% CI 0.8-1.0, p=0.84), MV repair 0.67 (95% CI 0.6-0.8, p<0.0001), MV bioprosthesis 0.82 (95% CI 0.81 (0.6-1.0, p=0.11) and bioprosthetic AV replacement 1.02 (95% CI 0.9-1.2, p=0.82). CONCLUSIONS: Compared to the general population, cardiac surgical patients have a shorter than expected life expectancy. We observed a survival benefit of mitral valve repair over replacement. We did not observe significant survival differences between off-pump and on-pump CAG, nor between bioprosthetic and mechanical replacement.
Assuntos
Bioprótese , Procedimentos Cirúrgicos Cardíacos , Implante de Prótese de Valva Cardíaca , Próteses Valvulares Cardíacas , Valva Aórtica/cirurgia , Feminino , Implante de Prótese de Valva Cardíaca/métodos , Humanos , Estudos Retrospectivos , Resultado do TratamentoRESUMO
OBJECTIVE: Our unit began a minimally invasive mitral surgery (MIMS) program utilising antegrade Custodiol solution as the sole cardioplegia. The aim of this paper is to report our results of this program. PATIENTS/METHODS: Early clinical outcomes were identified and assessed for the first consecutive 100 MIMS patients with comparisons made to a historical group operated via a sternotomy (n=113). The efficacy of myocardial protection was assessed using surrogate outcomes of myocardial protection with serial sodium concentrations also analysed. RESULTS: Six hours postoperatively 12 patients required inotropic support. Peak troponin-I in the first 24 hours was 5.1 (0.8-40 µg/L [median(range)]. Sodium levels decreased following administration of Custodiol but by six hours postoperatively the sodium had returned to greater than 130 mmol/L in all but five patients. Blood transfusion was smaller in the MIMS versus historical group (RBC 17% vs. 65%). MIMS patients had a shorter duration of ventilation, hospital stay and one-year mortality rate (0%). CONCLUSIONS: In this series of patients undergoing MIMS, single dose antegrade Custodiol offers satisfactory and safe myocardial protection. Early clinical outcomes were also satisfactory. Whilst our findings are observational, they nevertheless support the use of this less invasive approach to mitral surgery using single dose Custodiol for myocardial protection.
Assuntos
Soluções Cardioplégicas/administração & dosagem , Parada Cardíaca Induzida/métodos , Doenças das Valvas Cardíacas/cirurgia , Valva Mitral/cirurgia , Adulto , Idoso , Transfusão de Sangue , Cardiotônicos/uso terapêutico , Feminino , Glucose/administração & dosagem , Humanos , Tempo de Internação , Masculino , Manitol/administração & dosagem , Pessoa de Meia-Idade , Procedimentos Cirúrgicos Minimamente Invasivos/efeitos adversos , Procedimentos Cirúrgicos Minimamente Invasivos/métodos , Cuidados Pós-Operatórios , Cloreto de Potássio/administração & dosagem , Procaína/administração & dosagem , Sódio/sangue , Esternotomia/efeitos adversos , Troponina I/sangueRESUMO
PURPOSE OF REVIEW: Many patients presenting for surgical or other procedures in an ambulatory setting are taking new antiplatelet or anticoagulant agents. This review assesses how the novel features of these new agents affect the management of antithrombotic therapy in the ambulatory setting. RECENT FINDINGS: There have been very few studies investigating the relative risks of continuing or ceasing new antithrombotic agents. Recent reviews indicate that the new antithrombotic agents offer greater efficacy or ease of administration but are more difficult to monitor or reverse. They emphasize the importance of assessing the bleeding risk of the procedure, the thrombotic risk if the agent is ceased, and patient factors that increase the likelihood of bleeding. The timing of cessation of the agent, if required, depends on its pharmacokinetics and patients' bleeding risks. Patients at high risk of thrombotic complications may require bridging therapy. Once agreed upon, the perioperative plan should be made clear to all involved. SUMMARY: As there are few clinical studies to guide management, clinicians must make rational decisions in relation to continuing or ceasing new antithrombotic agents. This requires knowledge of their pharmacokinetics, and a careful multidisciplinary assessment of the relative thrombotic and bleeding risks in individual patients.
Assuntos
Procedimentos Cirúrgicos Ambulatórios/métodos , Fibrinolíticos/uso terapêutico , Trombose/tratamento farmacológico , HumanosRESUMO
PURPOSE OF REVIEW: New anticoagulants and new techniques bring challenges and opportunities to the practice of anaesthesia. Existing guidelines may not be up-to-date with these changes, so this review will examine the current research with a view to identifying deficiencies in existing guidelines, particularly those that may guide Australian anaesthetists. RECENT FINDINGS: The novel oral anticoagulants dabigatran and rivaroxaban, and the potent antiplatelet agents ticagrelor and prasugrel are available in Australia. Considerable research data support the benefit of using these drugs, but the risk profile is incompletely understood. The concept of damage control resuscitation is supported by plentiful, but potentially flawed, observational data, and also the technique may be associated with adverse effects. It remains difficult to firmly quantify the risks of using tranexamic acid or recombinant factor 7a in many clinical situations. SUMMARY: Despite much interesting recent research, few current guidelines are likely to require modification. Novel pharmaceuticals have risk profiles that are incompletely understood, but will only become evident on phase-4 testing. Australasian guidelines for reversal of warfarin may need to be updated to include advice on the use of recombinant factor 7a.
Assuntos
Transtornos da Coagulação Sanguínea/terapia , Hemorragia/terapia , Austrália , Fator VIIa/uso terapêutico , Humanos , Assistência Perioperatória , Inibidores da Agregação Plaquetária/uso terapêutico , Sistemas Automatizados de Assistência Junto ao Leito , Guias de Prática Clínica como Assunto , Trombocitopenia/tratamento farmacológico , Trombose/prevenção & controle , Ácido Tranexâmico/uso terapêuticoRESUMO
This cross-sectional overview of the second 4000 incidents reported to webAIRS has findings that are very similar to the previous overview of the first 4000 incidents. The distribution of patient age, body mass index and American Society of Anesthesiologists physical status was similar, as was anaesthetist gender, grade, location and time of day of incidents. About 35% of incidents occurred during non-elective procedures (vs. 33% in the first 4000 incidents). The proportion of incidents in the various main categories was also similar, with respiratory/airway being most common, followed by cardiovascular, medication-related and medical device or equipment-related incidents. Together these categories made up about 78% of all incidents in both overviews. The immediate outcome was comparable with reports of harm in about a quarter of incidents and a similar rate of deaths (4.7% vs. 4.2%). However, the proportion of patients who had received total intravenous anaesthesia was higher (17.6% vs. 7.7%) and the proportion of patients who received combined intravenous and inhalational anaesthesia was lower (52.3% vs. 58.4%), as was the proportion receiving local anaesthesia alone (1.6% vs. 6.7%). There was a small increase in the number of incidents resulting in unplanned admission to a high dependency or intensive care unit (18.1% vs. 13.5%). It is not clear whether these differences represent trends or random observations. About 48% of incidents were considered preventable by the reporters (vs. 52% in the first 4000). These findings support continued emphasis on human and system factors to promote and improve patient safety in anaesthesia care.
Assuntos
Anestesia por Inalação , Gestão de Riscos , Estudos Transversais , Humanos , Internet , Nova Zelândia/epidemiologiaRESUMO
Hypofibrinogenaemia during cardiac surgery may increase blood loss and bleeding complications. Viscoelastic point-of-care tests provide more rapid diagnosis than laboratory measurement, allowing earlier treatment. However, their diagnostic test accuracy for hypofibrinogenaemia has never been reviewed systematically. We aimed to systematically review their diagnostic test accuracy for the identification of hypofibrinogenaemia during cardiac surgery. Two reviewers assessed relevant articles from seven electronic databases, extracted data from eligible articles and assessed quality. The primary outcomes were sensitivity, specificity and positive and negative predictive values. A total of 576 articles were screened and 81 full texts were assessed, most of which were clinical agreement or outcome studies. Only 10 diagnostic test accuracy studies were identified and only nine were eligible (ROTEMdelta 7; TEG5000 1; TEG6S 1, n = 1820 patients) (ROTEM, TEM International GmbH, Munich, Germany; TEG, Haemonetics, Braintree, MA, USA). None had a low risk of bias. Four ROTEM studies with a fibrinogen threshold less than 1.5-1.6 g/l and FIBTEM threshold A10 less than 7.5-8 mm had point estimates for sensitivity of 0.61-0.88; specificity 0.54-0.94; positive predictive value 0.42-0.70; and negative predictive value 0.74-0.98 (i.e. false positive rate 30%-58%; false negative rate 2%-26%). Two ROTEM studies with higher thresholds for both fibrinogen (<2 g/l) and FIBTEM A10 (<9.5 mm) had similar false positive rates (25%-46%), as did the two TEG studies (15%-48%). This review demonstrates that there have been few diagnostic test accuracy studies of viscoelastic point-of-care identification of hypofibrinogenaemia in cardiac surgical patients. The studies performed so far report false positive rates of up to 58%, but low false negative rates. Further diagnostic test accuracy studies of viscoelastic point-of-care identification of hypofibrinogenaemia are required to guide their better use during cardiac surgery.
Assuntos
Afibrinogenemia , Procedimentos Cirúrgicos Cardíacos , Afibrinogenemia/diagnóstico , Alemanha , Humanos , Sistemas Automatizados de Assistência Junto ao Leito , TromboelastografiaRESUMO
BACKGROUND: It has been suggested that blood transfusion has an adverse effect on long-term health, mainly through immune modulation and tumor promotion. To further assess this concern, the authors have performed a prospective observational study with the hypothesis that after taking perioperative risk factors relevant to long-term survival into account, patients undergoing coronary artery surgery who receive a perioperative allogeneic blood transfusion have worse long-term survival than those who do not. METHODS: The health outcomes of 1,841 consecutive subjects who had isolated nonemergency first-time coronary artery surgery and who survived more than 60 days after surgery were determined by record linkage. The association between length of survival, blood products transfused, and risk factors for long-term survival at entry to the study were determined by Cox proportional hazards regression. RESULTS: A total of 1,062 subjects were transfused. Of these, 266 subjects died during a mean follow-up of 8.1 yr. Of subjects who were transfused, 27% had a new malignant condition recorded on the death certificate, compared with 43% who were not transfused. Older age, cerebrovascular disease, use of a mammary graft, chronic pulmonary disease, renal dysfunction, reduced left ventricular function, and preoperative anemia were predictive of reduced long-term survival. There was no association between transfusion of blood products and long-term survival. CONCLUSIONS: Patients who have undergone coronary artery surgery and who have received moderate amounts of blood as part of responsible and conservative management should be reassured that they are unlikely to experience a reduction in long-term survival.
Assuntos
Ponte de Artéria Coronária , Doença da Artéria Coronariana/mortalidade , Reação Transfusional , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Assistência Perioperatória , Modelos de Riscos Proporcionais , Estudos Prospectivos , Fatores de Risco , Análise de Sobrevida , Resultado do TratamentoAssuntos
Afibrinogenemia , Procedimentos Cirúrgicos Cardíacos , Humanos , Fibrinogênio , HemodiluiçãoAssuntos
Anestesia , Ensaios Clínicos como Assunto/métodos , Projetos de Pesquisa , Anestesia/estatística & dados numéricos , Anti-Hipertensivos/uso terapêutico , Pressão Sanguínea/efeitos dos fármacos , Ensaios Clínicos como Assunto/estatística & dados numéricos , Interpretação Estatística de Dados , Determinação de Ponto Final , Medicina Baseada em Evidências , Frequência Cardíaca/efeitos dos fármacos , Humanos , Hipertensão/etiologia , Hipertensão/fisiopatologia , Hipertensão/prevenção & controle , Intubação Intratraqueal/efeitos adversos , Projetos de Pesquisa/estatística & dados numéricos , Resultado do TratamentoRESUMO
Until recently, liver transplantation was contraindicated in Jehovah's Witness patients because of recipient-imposed restrictions on use of blood products. However, recent improvements in surgical and anaesthetic techniques and new procoagulant agents challenge this practice. We describe two Jehovah's Witness patients who had successful liver transplantation without blood transfusion. To our knowledge, these are the first such cases in Australasia. The techniques used to minimise blood loss and transfusion requirements could potentially benefit all patients undergoing major surgery.
Assuntos
Testemunhas de Jeová , Cirrose Hepática/cirurgia , Transplante de Fígado/métodos , Australásia , Carcinoma Hepatocelular/complicações , Humanos , Cirrose Hepática/etiologia , Neoplasias Hepáticas/complicações , Masculino , Pessoa de Meia-Idade , Deficiência de alfa 1-Antitripsina/complicaçõesRESUMO
OBJECTIVE: The aim of this audit was to determine the incidence of major gastrointestinal (GI) complications associated with intraoperative transesophageal echocardiography (TEE) in adult cardiac surgical patients in this institution. DESIGN: Retrospective database audit. SETTING: University-affiliated teaching hospital. PARTICIPANTS: Eight hundred fifty-nine consecutive cardiac surgical patients. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: The records of all patients who developed a major upper GI complication within 30 days of cardiac surgery between January 2001 and May 2003 were examined. The patients were identified by cross-referencing cardiac surgery and endoscopy databases. A major GI complication was defined as a perforation of the esophagus or stomach or upper GI bleeding requiring transfusion, endoscopic, or surgical intervention. Early presentation was defined as <24 hours; late presentation was defined as >24 hours. During the audit period, 859 patients underwent cardiac surgery. Five hundred sixteen patients had cardiac surgery with TEE (group 1), and 343 patients had cardiac surgery without TEE (group 2). Six patients were identified, 1.2% (95% confidence interval [CI], CI, 0.5%-2.5%) in group 1 who had a major upper GI complication consistent with TEE injury. Two patients, 0.38% (95% CI, 0.05%-1.40%), presented early, and 4 patients, 0.76% (95% CI, 0.21%-1.98%), presented late. One patient in group 2 developed a major upper GI complication, 0.29% (95% CI, 0.01%-1.6%). CONCLUSION: The incidence of major GI complications attributed to TEE in this group of cardiac surgical patients was higher than previously reported. Late presentation was more common than early presentation. Previous studies that have not included late presentations may have underestimated the true incidence of major GI complications related to TEE.
Assuntos
Procedimentos Cirúrgicos Cardíacos , Ecocardiografia Transesofagiana/efeitos adversos , Esôfago/lesões , Intestinos/lesões , Complicações Intraoperatórias/epidemiologia , Monitorização Intraoperatória/efeitos adversos , Estômago/lesões , Adulto , Idoso , Idoso de 80 Anos ou mais , Bases de Dados Factuais , Endoscopia , Feminino , Hematemese/etiologia , Humanos , Complicações Intraoperatórias/diagnóstico , Masculino , Pessoa de Meia-Idade , Complicações Pós-Operatórias/diagnóstico , Complicações Pós-Operatórias/epidemiologia , Estudos RetrospectivosRESUMO
OBJECTIVE: To compare the assessment of aspirin-related platelet dysfunction using Plateletworks (Helena Laboratories, Beaumont, TX), a new point-of-care platelet function analyzer, with turbidometric platelet aggregometry, in cardiac surgical patients. DESIGN: Prospective observational study. SETTING: University-affiliated teaching hospital. PARTICIPANTS: Fifty consecutive adult patients undergoing elective cardiac surgery for coronary artery bypass grafting or cardiac valve replacement. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Platelet function was assessed by Plateletworks and turbidometric platelet aggregometry before the commencement of anesthesia. Collagen, 10 microg/mL, was used as the agonist for both techniques. The area under the receiver-operator curve for the identification of recent aspirin ingestion (